- Business Wire•23 days agoImmunoGen to Present Preclinical Data Highlighting Potential of Combining Mirvetuximab Soravtansine with an Immune Checkpoint Inhibitor at SITC 2016 Annual Meeting
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced new preclinical data that demonstrate the potential for enhanced activity when combining mirvetuximab soravtansine with immune checkpoint inhibition.
- Business Wire•last monthImmunoGen Announces Preclinical Data Presentations for Two ADCs With Novel IGN Payloads at Upcoming 58th ASH Annual Meeting
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that new preclinical data on the Company’s novel IGN ADCs, IMGN632 and IMGN779, will be presented at the upcoming American Society of Hematology annual meeting, which is being held December 3-6, 2016 in San Diego, CA.
IMGN : Summary for ImmunoGen, Inc. - Yahoo Finance
ImmunoGen, Inc. (IMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||1.87 x 100|
|Ask||2.70 x 500|
|Day's Range||1.78 - 1.94|
|52 Week Range||1.51 - 14.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.05|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|